Vellanki P, et al. - In this prospective open-label multicentre study, researchers examined the data to quantify the glycaemic effectiveness and safety of linagliptin vs basal-bolus insulin regimen in hospitalized surgical patients with type 2 diabetes (T2D). They observed a higher level of mean daily blood glucose (BG) in the linagliptin group as compared to the basal-bolus group (9.5 ± 2.6 vs 8.8 ± 2.3 mmol/L/dL) with a mean daily BG difference of 0.6 mmol/L. They reported less hypoglycaemic events (1.6% vs 11%; 86% relative risk reduction) with linagliptin with comparable supplemental insulin and fewer daily insulin injections (2.0 ± 3.3 vs 3.1 ± 3.3) as compared to the basal-bolus group. They concluded daily linagliptin a safe and efficient option to multi-dose insulin therapy for subjects with T2D undergoing non-cardiac surgery and exhibiting mild to moderate hyperglycemia (BG < 11.1 mmol/L).